# Aarti Drugs Limited (AARTIDRUGS)

> AARTIDRUGS closed at ₹435.20 on 30 Oct 2026, trailing P/E 20.8, market cap ₹3,972 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Aarti Drugs Limited (NSE: AARTIDRUGS) closed at ₹435.20 on 30 Oct 2026, -15.9% over one year, against a 52-week range of ₹318.95 – ₹534.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 31 Jul 2026) it reported revenue of ₹703 cr and net profit of ₹50 cr, a 7.1% net margin; revenue grew 19.0% and profit grew 35.5% year on year.

On four consecutive filed quarters its trailing P/E is 20.8; since 12 May 2025 its own P/E has ranged from 14.4 to 29.7 (median 20.7), and today's reading is higher than 51% of those 364 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 13.0%, ROCE 16.6%, debt-to-equity 0.37, Piotroski F-score 7 of 9.

Against 66 Healthcare peers on NSE: Net margin higher than 17% of 64 sector peers; PBT margin higher than 16% of 64 sector peers; ROE higher than 45% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹435.20 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -0.5% / +18.7% / -15.9% |
| 52-week low – high | ₹318.95 – ₹534.00 |
| Market capitalisation | ₹3,972 cr |
| Trailing P/E | 20.8 |
| Price / book | 2.56 |
| EV / EBITDA | 13.6 |
| Earnings yield | 4.8% |
| TTM EPS | ₹20.95 |
| TTM net profit | ₹191 cr |
| Quarter revenue | ₹703 cr |
| Quarter net profit | ₹50 cr |
| Net margin | 7.1% |
| Revenue growth (YoY) | +19.0% |
| Profit growth (YoY) | +35.5% |
| Return on equity | 13.0% |
| ROCE | 16.6% |
| Debt / equity | 0.37 |
| Current ratio | 1.59 |
| Free cash flow | ₹80 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹5.8 cr |

## Questions

### What is the P/E ratio of Aarti Drugs Limited?

Aarti Drugs Limited's trailing P/E is 20.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 12 May 2025 its P/E has ranged 14.4–29.7.

### What were Aarti Drugs Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Aarti Drugs Limited reported revenue of ₹703 cr and net profit of ₹50 cr (consolidated), filed with the exchange on 31 Jul 2026.

### What is Aarti Drugs Limited's ROE?

Return on equity is 13.0% based on the balance sheet dated 31 Mar 2026.

### Does Aarti Drugs Limited have debt?

Debt-to-equity is 0.37 on the balance sheet dated 31 Mar 2026.

### What is AARTIDRUGS's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, AARTIDRUGS traded between ₹318.95 and ₹534.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/AARTIDRUGS

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._